Effects of Sublingual Immunotherapy on Grasspollen Allergy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00150514|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : September 8, 2005
|Condition or disease||Intervention/treatment||Phase|
|Hayfever||Drug: Oralgen Procedure: Nasal biopsy Procedure: Nasal washing Procedure: Peak nasal inspiratory flow||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose.|
|Study Start Date :||January 2002|
|Estimated Study Completion Date :||December 2006|
- Double blind placebo controlled evaluation of the immunological effects of SLIT on the nasal mucosal tissue of adult humans with sever
- I. Correlating immunological effects to a retrospective subjective complaint reduction.
- II. Rescue medication decrease through SLIT.
- III. Determining the effects of SLIT on decongestion.
- IV. Assessment of treatment compliance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150514
|Radboud university hospital|
|Nijmegen, Gelderland, Netherlands, 6500|
|Study Chair:||K Ingels, MD||Radboud University|